Effect of routine iron supplementation with or without folic acid on anemia during pregnancy by Yakoob, Mohammad Yawar & Bhutta, Zulfiqar Ahmed
eCommons@AKU
Woman and Child Health Division of Woman and Child Health
April 2011
Effect of routine iron supplementation with or
without folic acid on anemia during pregnancy
Mohammad Yawar Yakoob
Aga Khan University
Zulfiqar Ahmed Bhutta
Aga Khan University
Follow this and additional works at: http://ecommons.aku.edu/
pakistan_fhs_mc_women_childhealth_wc
Part of the Maternal and Child Health Commons
Recommended Citation
Yakoob, M., Bhutta, Z. A. (2011). Effect of routine iron supplementation with or without folic acid on anemia during pregnancy. BMC
Public Health, 11, S21-S21.
Available at: http://ecommons.aku.edu/pakistan_fhs_mc_women_childhealth_wc/23
REVIEW Open Access
Effect of routine iron supplementation with or
without folic acid on anemia during pregnancy
Mohammad Yawar Yakoob, Zulfiqar A Bhutta*
Abstract
Introduction: Iron deficiency is the most prevalent nutrient deficiency in the world, particularly during pregnancy.
According to the literature, anemia, particularly severe anemia, is associated with increased risk of maternal
mortality. It also puts mothers at risk of multiple perinatal complications. Numerous studies in the past have
evaluated the impact of supplementation with iron and iron-folate but data regarding the efficacy and quality of
evidence of these interventions are lacking. This article aims to address the impact of iron with and without folate
supplementation on maternal anemia and provides outcome specific quality according to the Child Health
Epidemiology Reference Group (CHERG) guidelines.
Methods: We conducted a systematic review of published randomized and quasi-randomized trials on PubMed and
the Cochrane Library as per the CHERG guidelines. The studies selected employed daily supplementation of iron with
or without folate compared with no intervention/placebo, and also compared intermittent supplementation with the
daily regimen. The studies were abstracted and graded according to study design, limitations, intervention specifics and
outcome effects. CHERG rules were then applied to evaluate the impact of these interventions on iron deficiency
anemia during pregnancy. Recommendations were made for the Lives Saved Tool (LiST).
Results: After screening 3550 titles, 31 studies were selected for assessment using CHERG criteria. Daily iron
supplementation resulted in 73% reduction in the incidence of anemia at term (RR = 0.27; 95% CI: 0.17 – 0.42;
random effects model) and 67% reduction in iron deficiency anemia at term (RR = 0.33; 95% CI: 0.16 – 0.69;
random model) compared to no intervention/placebo. For this intervention, both these outcomes were graded as
‘moderate’ quality evidence. Daily supplementation with iron-folate was associated with 73% reduction in anemia
at term (RR = 0.27; 95% CI: 0.12 – 0.56; random model) with a quality grade of ‘moderate’. The effect of the same
intervention on iron deficiency anemia was non-significant (RR = 0.43; 95% CI: 0.17 – 1.09; random model) and was
graded as ‘low’ quality evidence. There was no difference in rates of anemia at term with intermittent iron-folate
vs. daily iron-folate supplementation (RR = 1.61; 95% CI: 0.82 –3.14; random model).
Conclusion: Applying the CHERG rules, we recommend a 73% reduction in anemia at term with daily iron (alone)
supplementation or iron/folate (combined) vs. no intervention or placebo; for inclusion in the LiST model. Given
the paucity of studies of intermittent iron or iron-folate supplementation, especially in developing countries, we
recommend further evaluation of this intervention in comparison with daily supplementation regimen.
Introduction
Around 2 billion people, amounting to over 30% of the
world’s population are anemic, mainly due to iron defi-
ciency [1]. Iron deficiency is the most prevalent and also
the most neglected nutrient deficiency in the world,
particularly among pregnant women and children, espe-
cially in developing countries [2]. It is also significantly
prevalent in industrialized countries. Estimates say that
globally, fifty six million pregnant women (41.8% of the
total) are affected with anemia, again mostly due to iron
deficiency [3]. In developing countries, this proportion
can be as high as 80% like in South Asia [4], making
pregnant mothers susceptible to increased risk of mor-
tality and decreased work capacity. It may also lead to
other perinatal complications like pre-eclampsia, low
birth weight, prematurity and perinatal mortality [5]. It
is the poorest, most vulnerable and least educated who
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are disproportionately affected by iron deficiency, and it
is this group that stands to gain the most by its
reduction.
Anemia, as defined by low hemoglobin or hematocrit,
is commonly used to assess the severity of iron defi-
ciency in populations without high rates of malaria. The
high physiological requirement for iron in pregnancy is
difficult to meet with most diets. Therefore, pregnant
women should routinely receive iron supplementation,
especially in developing countries. Prenatal iron supple-
mentation is not compulsory in many industrialized
countries and the recommended dose is usually small
(30 mg ferrous iron daily) [6]. However, for developing
countries, the recommendation is a daily dose of 60 mg
of iron for pregnant, non-anemic women for six months
and an increased dose of 120 mg of iron daily if the
duration of supplementation is shorter, if iron deficiency
prevalence in women of a given country is high, and if
pregnant women are anemic. This supplement should
include 400 µg of folic acid or lower doses if this
amount is not available [7].
Earlier studies have provided sufficient evidence to
show that iron supplementation with or without folic
acid results in a significant reduction in the incidence of
anemia during pregnancy [2,8]. There has also been a
limited impact of iron supplementation in community
settings owing to lack of compliance and poor infra-
structure [9]. However, data regarding quality of evi-
dence for the effectiveness of iron during pregnancy are
lacking. Besides, the data on studies in developing coun-
tries have not been presented separately. This article is
one of the series of papers that aim to determine effi-
cacy of interventions for recommendations into the
Lives Saved Tool (LiST), especially in developing coun-
tries and is, therefore, different from previously pub-
lished systematic reviews. In LiST, increases in coverage
of an intervention results in a reduction of risk factor or
one or more causes of mortality. In this review, the
recommendations are made based on application of
adapted Grading of Recommendations, Assessment,
Development and Evaluation (GRADE) approach for the
quality of evidence and use of the Child Health Epide-
miology Reference Group (CHERG) rules. For more
details of the review methods, the adapted GRADE
approach or the LiST model, see the methods paper for
by CHERG group [10].
Methods
Searching
We systematically reviewed all published literature up to
June 21, 2010 to identify studies of iron supplementa-
tion with or without folic acid during pregnancy on
maternal anemia. As per the Child Health Epidemiology
Reference Group (CHERG) systematic review guidelines
[10], we searched PubMed and the Cochrane Library,
and included publications in any language available in
these databases. Every effort was made to gather unpub-
lished data when reports were available for full abstrac-
tion. Previous reviews on the topic were also hand-
searched to look for relevant studies [2,8,11]. We used
the Medical Subject Heading Terms (MeSH) and free
text terms for the search strategy using a combination
of terms for iron, folic acid and pregnancy, as follows:
("Iron"[Mesh OR “Folic Acid"[Mesh] OR iron OR folic
acid OR folate) AND ("Anemia"[Mesh] OR “Anemia,
Iron-Deficiency"[Mesh] OR anemia) AND (pregnancy
OR maternal)
Inclusion/exclusion criteria
We limited our search to randomized and quasi-rando-
mized trials conducted in both developed and develop-
ing countries, comparing the effects of preventive
prenatal oral iron or iron + folic acid supplements
among pregnant women versus no treatment/placebo.
The developing countries were defined as countries with
Gross National Income per capita (GNI) below US
$11,905, according to World Bank [12]. Pregnant
mothers could be of any age or parity. Studies were
included if iron or iron-folate was given alone to the
intervention group. Those studies were excluded that
assessed the effects of multiple combinations of vitamins
and minerals except even if iron/iron-folate was the
only difference among the study groups (arms). All
included studies contained a placebo or a suitable con-
trol group that did not contain iron or iron-folate.
There were no limits on gestational age at the time of
enrolment in the study and the duration of supplemen-
tation. Studies of peri-conceptional or postpartum iron/
iron-folate supplementation were excluded. Studies of
fortification of iron/iron-folate in food or studies in
which iron was given in forms other than oral supple-
ments like powder were excluded. Similarly, studies
where iron or iron-folate was given in any parenteral
formulation were excluded. Other exclusion criteria
included trials of supplementation with multiple micro-
nutrients (MMN) containing iron or iron + folic acid in
comparison to supplementation with iron or iron + folic
acid alone as this has been reviewed in another paper of
this series [13]. Studies where iron/iron-folate was given
to anemic pregnant women as a medical treatment were
also excluded as the primary objective of this review was
to assess the efficacy of preventive iron/folate supple-
mentation for anemia during pregnancy. The therapeu-
tic role of iron for anemia during pregnancy had been
reviewed elsewhere [14]. We conducted sub-group ana-
lyses with respect to study country setting i.e. developed
or developing. However, we did not specifically evaluate
minor adverse effects of the supplements such as
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nausea, vomiting, headache or constipation among the
pregnant mothers.
Abstraction, analyses and summary measures
Studies were included if data from one of the following
outcomes was provided: anemia at term, iron deficiency
anemia at term, severe anemia at term and severe ane-
mia at any time during the second and third trimester.
All outcome measures to be included were determined a
priori. The interventions described in this review can be
subdivided into four categories: 1) daily iron supplemen-
tation alone compared to placebo/control, 2) weekly
iron supplementation alone compared to daily regimen,
3) daily supplementation of iron and folic acid versus
placebo/control and 4) weekly supplementation of iron
and folic acid versus daily supplementation.
All studies that met final inclusion and exclusion cri-
teria were double-data abstracted into a standardized
form for each outcome of interest. We abstracted key
variables with regard to the study identifiers and con-
text, study design and limitations, intervention specifics,
and outcome effects. Each study was assessed and
graded according to the CHERG adaptation of the
GRADE technique [15]. Studies received an initial score
of high if they were RCTs or cluster-RCTs (cRCTs).
The grade was decreased by 0.5 - 1 point for each study
design limitation like inadequate methods of sequence
generation, allocation concealment and attrition > 20%
etc. In addition, studies reporting an intent-to-treat ana-
lysis or with statistically significant strong levels of asso-
ciation (> 80% reduction) received 0.5 – 1.0 grade
increase. Any study with a final grade of very low was
excluded on the basis of inadequate study quality.
For any outcome with more than one study, we con-
ducted a meta-analysis and reported the Mantel-Haens-
zel pooled relative risk and corresponding 95%
confidence interval (CI). In case of heterogeneity (P <
0.1 and I2 > 50%), the random effect model (DerSimo-
nian-Laird) pooled relative risk and corresponding 95%
CI was used, especially where there was unexplained
heterogeneity such as major differences in study design
[10]. All analyses were conducted using RevMan 5 sta-
tistical software.
We summarized the evidence based on outcome by
including assessment of the study quality and quantita-
tive measures according to standard guidelines [10] for
each outcome. For the outcomes of interest, namely the
effect of iron/iron-folate on maternal anemia, we applied
the CHERG Rules for Evidence Review [10] to recom-
mend final estimates for reduction in anemia with iron
or iron-folate supplementation. Additional file 1 con-
tains a list of studies from the search that were excluded
from the meta-analyses with a brief explanation for why
the study was excluded.
Definitions
Anemia was defined as hemoglobin (Hb) level of less
than 110g/L and severe anemia was defined as hemoglo-
bin level of less than 70g/L. Iron deficiency anemia was
defined as Hb less than 110 g/L and at least one addi-
tional laboratory indicator (mean cell volume, haemo-
globin concentration, serum ferritin, erythrocyte
protoporphyrin concentrations etc) of iron deficiency .
Results
The search generated 3550 hits on PubMed and 290 in
Cochrane Library that were screened and after removing
duplicates, 81 abstracts were preliminarily selected.
These were reviewed in detail, including full texts and
finally 31 [16-47] studies were selected for inclusion in
this paper. A detailed account of the number of
abstracts and titles scanned is given as a flow chart
(Figure 1). Table 1 gives the summary of the quality of
evidence and the impact estimates of different
interventions.
Anemia at term
This outcome was reported by 18 studies [16,17,19-21,
23,24,27,29,30,32-34,37-39,41,47]. Daily supplementation
with iron only versus no intervention/placebo was evalu-
ated by 14 studies [17,19,21,23,24,27,29,30,33,
34,37-39,41]. There was a statistically significant 73%
reduction in the incidence of anemia at term (RR =
0.27; 95% CI: 0.17 – 0.42; random model) (Figure 2).
There were three studies [16,17,21] that evaluated daily
supplementation with iron and folic acid both versus
no intervention/placebo and pooled data also showed a
significant 73% reduction in anemia at term (RR =
0.27; 95% CI: 0.12 – 0.56; random model) (Figure 3).
There was, however, no difference between intermit-
tent iron-folic acid supplementation vs. daily iron-
folate on this outcome based on three studies
[20,32,47] (RR = 1.61; 95% CI: 0.82 –3.14; random
model) (Figure 4).
Iron deficiency anemia at term
This outcome was reported by seven studies
[23,27,31,33,34,43,45]. Daily supplementation with iron
alone versus no intervention/placebo had a significant
67% reduction in incidence of iron deficiency anemia at
term based on six studies [23,27,33,34,43,45] (RR = 0.33;
95% CI: 0.16 – 0.69; random model). There was one
study [31] on daily iron-folic acid versus no interven-
tion/placebo and the effect was large but non-significant
(RR = 0.43; 95% CI: 0.17 – 1.09; random model)
Severe anemia at term
This outcome was estimated by 13 studies
[16,18,20,23,27,30-35,41,45]. Daily iron supplementation
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versus no intervention/placebo, as seen in 8 studies
[18,23,27,30,33,34,41,45], had a non significant adverse
impact on severe anemia at term (RR = 4.83; 95% CI:
0.23 - 99.88; random model). This result was primarily
based on one study [33] as all the other studies had
zero events in both groups. Three studies evaluated the
impact of daily supplementation with iron and folate
both on severe anemia at term [16,18,31], but the num-
ber of events in these studies in both groups was nil.
Intermittent supplementation with iron and folate vs.
daily supplementation of same micronutrients also
yielded no severely anemic patients in the intervention
and control groups in the three studies that looked at
this outcome [20,32,35].
Severe anemia at any time during second and
third trimester
Severe anemia during second and third trimester was
reported by 19 studies [16,18,22,23,25,27,28,30-
32,36,40,42,44-46]. Daily iron alone compared to no
supplementation had no impact on severe anemia in
second and third trimester based on nine studies
[18,22,23,27,28,30,33,34,45], (RR = 0.48; 95% CI: 0.01 –
34.52; random model), with only two studies [22,33]
having events greater than zero in the intervention and
control groups. For intermittent iron alone vs. daily iron
alone, there were two studies [36,44] that looked at this
outcome and both had zero events in the two groups.
Daily iron-folic acid versus no intervention/placebo also
had no effect on severe anemia at any time during sec-
ond and third trimester based on four studies
[16,18,22,31] (RR = 0.11; 95% CI: 0.01 – 0.83), with zero
events in three of these studies in both groups, except
one [22]. Intermittent iron-folate vs. daily iron-folate
outcome included 6 studies [25,32,35,40,42,46] and
events were nil in both groups in all these six studies.
Discussion
Iron supplementation alone or in combination with folic
acid has been associated with the well being of the
mother and fetus. It leads to a significant reduction in
anemia incidence during pregnancy and, thus, plays a
vital role in reducing maternal morbidity and mortality.
The results of our review were consistent with those of
an earlier Cochrane review by Pena Rosas and Viteri [2]
that also showed a significant reduction in incidence of
Screenedforeligibility
81abstractsselectedfor
detailedevaluation
Reviewedpapersfor
eligibility
4reviews
Anemiaatterm
(n=18)
Severeanemiaatanytime
duringthesecondand
thirdtrimester(n=19)
Severeanemiaatterm
(n=13)
31papersidentifiedfor
dataabstraction
Excluded:26:reasonsgivenin
Table2
Excluded:20ontreatmentof
anemia
3550abstracts
Irondeficiency
anemiaatterm(n=7)
Figure 1 Flow chart of the literature search.
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anemia and iron deficiency anemia at term with daily
iron supplementation and that of anemia at term due to
daily iron-folate supplementation versus no interven-
tion/placebo.
The pooled analysis of effect of daily iron supplemen-
tation vs. control had a high heterogeneity (fig 2). The
most likely explanation of this substantial statistical het-
erogeneity (I2 =73 %) is the variable effect size of the
studies which in turn depend on the baseline anemia
status of the study population. An important observa-
tion to make is that the direction effect in all the studies
was in the same direction. We can expect that biologic
effect of iron supplementation would differ based on
prevalence of anemia in the study population. To further
elaborate on this observation, we conducted a post hoc
subgroup analysis based on baseline anemia status of
the study population (data not shown). There were
seven studies that included only non-anemic pregnant
women based on laboratory evidence of absence of ane-
mia (hemoglobin < 110 g/L) [21,23,24,27,29,33,39] and
in other seven studies, population was that of mixed sta-
tus [17,19,30,34,37,38,41]. Pooled estimates for non-ane-
mic women were less heterogeneous (I2 =47%) and size
of summary estimate was less prominent (RR 0.31, 95 %
CI 0.19-0.52) compared to that of mixed population that
had more heterogeneous (I2=83%) and more prominent
results (RR 0.22, 95 % CI 0.11-0.47). This shows a
strong biologic effect in favor of the intervention and
also indicates that effect of Iron supplementation would
depend on degree of baseline anemia in the study
population.
CHERG rules were applied to the collective outcomes
of anemia for recommendation of iron deficiency ane-
mia into the LiST model. Daily supplementation with
iron led to 73% reduction in incidence of anemia at
term as compared to no supplementation. This interven-
tion had a ‘moderate’ quality evidence owing to some
limitations in included studies like unclear
[17,21,24,30,34,38,39,41] or inadequate sequence genera-
tion [19], and high loss to follow up [17,23,27]. Another
limitation was that all the studies in the pooled analysis
were not conducted in developing countries. In any
case, based on strong biologic plausibility and consistent
direction of effect across the studies, we recommend
a 73 % reduction in anemia at term with iron supple-
mentation during pregnancy, for inclusion in the LiST
model. Daily supplementation with iron and folate led
to 73% reduction in incidence of anemia at term when
Table 1 Quality assessment of trials of iron and/or folate on the incidence of anemia during pregnancy
Quality Assessment Summary of Findings
No of
studies
(ref)
Design Limitations Consistency Directness No of events
Generalizability to
population of
interest
Generalizability
to intervention
of interest
Intervention Control Relative
Risk
(95% CI)
Daily iron versus no intervention/placebo Anemia at term: Moderate outcome specific quality
14 RCT/
quasi
RCT
Studies with unclear or
inadequate sequence
generation and high loss
to follow-up
All studies show
direction of benefit,
but high
heterogeneity
Only two studies in
developing
countries, rest in
developed nations
Yes 114 313 RR
(random)
= 0.27 [
0.17, 0.42
]
Daily iron versus no intervention/placebo: Iron deficiency anemia at term: Moderate outcome specific quality
6 RCT/
quasi
RCT
Studies with unclear or
inadequate sequence
generation and high loss
to follow-up
All studies show
direction of benefit,
with borderline
heterogeneity
Only one study in
developing country,
rest in developed
Yes 25 68 RR
(random)
= 0.33 [
0.16, 0.69
]
Daily iron and folic acid versus no intervention/placebo: Anemia at term: Moderate outcome specific quality
3 RCT/
quasi-
RCTs
High loss to follow-up
and unclear sequence
generation
Two studies show
direction of benefit;
while the third study
had zero events
Only one study in
developing country,
rest in developed
Yes 17 49 RR
(random)
= 0.27 [
0.12, 0.56
]
Daily iron and folic acid versus no intervention/placebo: Iron deficiency anemia at term: Low outcome specific quality
1 RCT Allocation concealment
unclear and blinding
inadequate
One study only In a developed
country
Yes 12 5 RR
(random)
= 0.43
[0.17,
1.09]
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compared with no supplementation. We recommend
this estimate for reduction in anemia at term for inclu-
sion in the LiST model. The quality of evidence regard-
ing this intervention had to be down-graded from ‘high’
to moderate due to some limitations like high loss to
follow up [17] and unclear sequence generation [21] and
also the fact that all the studies were not conducted in
developing countries.
Our results show that there was not much difference
in effect between iron alone and iron-folate combined.
The effect sizes were similar for both the analyses but
CIs were wider for that of iron/folate, mainly due to less
number of studies in the pooled analysis. This shows
that we can expect a similar biological effect when the
iron is supplemented alone or in combination with
folate. We did a subgroup for developing and developed
countries. There were not sufficient studies from devel-
oping countries for all the analyses. An important obser-
vation to make in figure 2 is that even though there
were two studies from developing countries, the results
were very consistent (I2=0%). Even though there are not
a lot of randomized trials conducted in developing
countries but we can suggest that iron supplementation
would be much effective in developing world by looking
at biological plausibility of the intervention. The popula-
tions that are most at risk for iron deficiency and IDA
are young children and women of reproductive age,
especially during pregnancy. The global estimates on
prevalence of anemia showed that more than half the
pregnant women and young children are anemic in
Study or Subgroup
1.1.1 Developing countries
Batu 1976
Preziosi 1997
Subtotal (95% CI)
Total events
Heterogeneity: Tau² = 0.00; Chi² = 0.07, df = 1 (P = 0.79); I² = 0%
Test for overall effect: Z = 4.98 (P < 0.00001)
1.1.2 Developed countries
Chanarin 1971
Chisholm 1966
Cogswell 2003
De Benaze 1989
Eskeland 1997
Hemminki 1991
Holly 1955
Makrides 2003
Milman 1991
Pritchard 1958
Puolakka 1980
Romslo 1983
Subtotal (95% CI)
Total events
Heterogeneity: Tau² = 0.37; Chi² = 24.69, df = 11 (P = 0.01); I² = 55%
Test for overall effect: Z = 5.90 (P < 0.00001)
Total (95% CI)
Total events
Heterogeneity: Tau² = 0.38; Chi² = 48.88, df = 13 (P < 0.00001); I² = 73%
Test for overall effect: Z = 5.69 (P < 0.00001)
Events
17
41
58
1
3
12
3
0
15
1
14
0
6
0
1
56
114
Total
36
99
135
49
60
90
44
24
1336
94
200
100
74
16
22
2109
2244
Events
29
69
98
9
20
11
8
7
56
23
30
15
23
6
7
215
313
Total
34
98
132
46
60
62
25
21
1358
55
193
107
49
15
23
2014
2146
Weight
12.7%
13.3%
26.0%
3.7%
7.3%
10.1%
6.8%
2.2%
11.4%
3.8%
11.2%
2.2%
9.5%
2.2%
3.7%
74.0%
100.0%
M-H, Random, 95% CI
0.55 [0.38, 0.80]
0.59 [0.45, 0.77]
0.58 [0.46, 0.72]
0.10 [0.01, 0.79]
0.15 [0.05, 0.48]
0.75 [0.35, 1.59]
0.21 [0.06, 0.73]
0.06 [0.00, 0.97]
0.27 [0.15, 0.48]
0.03 [0.00, 0.18]
0.45 [0.25, 0.82]
0.03 [0.00, 0.57]
0.17 [0.08, 0.39]
0.07 [0.00, 1.18]
0.15 [0.02, 1.12]
0.21 [0.12, 0.35]
0.27 [0.17, 0.42]
Experimental (daily) Control (no iron) Risk Ratio Risk Ratio
M-H, Random, 95% CI
0.002 0.1 1 10 500
Favours experimental Favours control
Figure 2 Impact of daily iron supplementation compared with no supplementation on anemia at term (hemoglobin less than 110g/L)
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Study or Subgroup
5.1.1 Developing countries
Batu 1976
Subtotal (95% CI)
Total events
Heterogeneity: Not applicable
Test for overall effect: Z = 3.70 (P = 0.0002)
5.1.2 Developed countries
Barton 1994
Chisholm 1966
Subtotal (95% CI)
Total events
Heterogeneity: Not applicable
Test for overall effect: Z = 4.31 (P < 0.0001)
Total (95% CI)
Total events
Heterogeneity: Tau² = 0.18; Chi² = 2.50, df = 1 (P = 0.11); I² = 60%
Test for overall effect: Z = 3.45 (P = 0.0006)
Test for subgroup differences: Not applicable
Events
10
10
0
7
7
17
Total
32
32
53
123
176
208
Events
29
29
0
20
20
49
Total
34
34
44
60
104
138
Weight
57.8%
57.8%
42.2%
42.2%
100.0%
M-H, Random, 95% CI
0.37 [0.22, 0.62]
0.37 [0.22, 0.62]
Not estimable
0.17 [0.08, 0.38]
0.17 [0.08, 0.38]
0.27 [0.12, 0.56]
Experimental (daily) Control (no iron) Risk Ratio Risk Ratio
M-H, Random, 95% CI
0.01 0.1 1 10 100
Favours experimental Favours control
Figure 3 Impact of daily supplementation with iron and folate compared with no supplementation on anemia at term (hemoglobin
less than 110g/L)
Figure 4 Impact of intermittent supplementation with iron and folic acid compared with daily supplementation on anemia at term
(hemoglobin less than 110g/L)
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Southeast Asia, West Pacific and Africa [48]. This shows
that amount of effect would be substantially high in
developing countries however more efficacy trials are
required to determine the conduct of the intervention.
Weekly iron and folic acid supplementation (WIFS) is
a relatively new phenomenon, and there is very little
data at the moment comparing weekly supplementation
with daily dosage. Weekly iron and folic acid supple-
mentation, in synchrony with the turnover of mucosal
cells, may be a promising substitute for daily iron sup-
plementation and has been proposed as a more efficient
preventive approach in public health programs [49,50].
The WHO says that WIFS should be considered a strat-
egy for prevention of iron deficiency in population
groups where the prevalence of anemia is above 20%
among women of reproductive age and mass fortifica-
tion programs of staple foods with iron and folic acid
are unlikely to be implemented within 1-2 years. How-
ever, conclusive data regarding its efficacy as compared
to the daily regimen are not yet available. Weekly
dosage may have benefits of reduced side effects and
increased compliance, but more field randomized con-
trolled trials are needed to establish the efficacy of
weekly supplementation compared to daily regimen.
Conclusions
Iron supplementation has a significant benefit in redu-
cing anemia and iron deficiency anemia at term. Iron in
combination with folic acid also has a beneficial impact
on anemia at term and should be routinely used in
pregnant women at least in developing countries to
reduce the incidence of anemia due to increased
demands during pregnancy.
Additional material
Additional File 1: Excluded Studies and Reasons for Exclusion. This
is an excel file.
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